217 related articles for article (PubMed ID: 24840518)
1. Management of advanced uterine leiomyosarcoma.
Hyman DM; Grisham RN; Hensley ML
Curr Opin Oncol; 2014 Jul; 26(4):422-7. PubMed ID: 24840518
[TBL] [Abstract][Full Text] [Related]
2. Uterine leiomyosarcoma: Epidemiology, contemporary treatment strategies and the impact of uterine morcellation.
Ricci S; Stone RL; Fader AN
Gynecol Oncol; 2017 Apr; 145(1):208-216. PubMed ID: 28209496
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological treatment for uterine leiomyosarcomas.
Gadducci A; Guerrieri ME
Expert Opin Pharmacother; 2015 Feb; 16(3):335-46. PubMed ID: 25418060
[TBL] [Abstract][Full Text] [Related]
4. Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.
Cui RR; Wright JD; Hou JY
BJOG; 2017 Jun; 124(7):1028-1037. PubMed ID: 28128524
[TBL] [Abstract][Full Text] [Related]
5. The role of adjuvant therapy in uterine leiomyosarcoma.
Ducie JA; Leitao MM
Expert Rev Anticancer Ther; 2016; 16(1):45-55. PubMed ID: 26558647
[TBL] [Abstract][Full Text] [Related]
6. Systematic chemotherapy for inoperable, locally advanced, recurrent, or metastatic uterine leiomyosarcoma: a systematic review.
Gupta AA; Yao X; Verma S; Mackay H; Hopkins L;
Clin Oncol (R Coll Radiol); 2013 Jun; 25(6):346-55. PubMed ID: 23295078
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.
Pautier P; Floquet A; Chevreau C; Penel N; Guillemet C; Delcambre C; Cupissol D; Selle F; Isambert N; Piperno-Neumann S; Thyss A; Bertucci F; Bompas E; Alexandre J; Collard O; Lavau-Denes S; Soulié P; Toulmonde M; Le Cesne A; Lacas B; Duffaud F;
Lancet Oncol; 2015 Apr; 16(4):457-64. PubMed ID: 25795402
[TBL] [Abstract][Full Text] [Related]
8. The biology and treatment of leiomyosarcomas.
Kerrison WGJ; Thway K; Jones RL; Huang PH
Crit Rev Oncol Hematol; 2023 Apr; 184():103955. PubMed ID: 36893945
[TBL] [Abstract][Full Text] [Related]
9. Optimal management of uterine leiomyosarcoma.
O'Cearbhaill R; Hensley ML
Expert Rev Anticancer Ther; 2010 Feb; 10(2):153-69. PubMed ID: 20131992
[TBL] [Abstract][Full Text] [Related]
10. Metastatic uterine leiomyosarcoma regression using an aromatase inhibitor.
Hardman MP; Roman JJ; Burnett AF; Santin AD
Obstet Gynecol; 2007 Aug; 110(2 Pt 2):518-20. PubMed ID: 17666649
[TBL] [Abstract][Full Text] [Related]
11. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in the treatment of sarcomas in gynecology.
Lange SS; Novetsky AP; Powell MA
Discov Med; 2014 Sep; 18(98):133-40. PubMed ID: 25227754
[TBL] [Abstract][Full Text] [Related]
13. Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.
Akin S; Dizdar O; Karakas Y; Turker A; Kars A
Curr Probl Cancer; 2018; 42(3):344-349. PubMed ID: 29576383
[TBL] [Abstract][Full Text] [Related]
14. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
15. Management of sarcomas of the uterus.
Novetsky AP; Powell MA
Curr Opin Oncol; 2013 Sep; 25(5):546-52. PubMed ID: 23942299
[TBL] [Abstract][Full Text] [Related]
16. Uterine leiomyosarcoma: A review of the literature and update on management options.
Roberts ME; Aynardi JT; Chu CS
Gynecol Oncol; 2018 Dec; 151(3):562-572. PubMed ID: 30244960
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced uterine leiomyosarcoma with aromatase inhibitors.
O'Cearbhaill R; Zhou Q; Iasonos A; Soslow RA; Leitao MM; Aghajanian C; Hensley ML
Gynecol Oncol; 2010 Mar; 116(3):424-9. PubMed ID: 19932916
[TBL] [Abstract][Full Text] [Related]
18. Options for Adjuvant Therapy for Uterine Leiomyosarcoma.
Friedman CF; Hensley ML
Curr Treat Options Oncol; 2018 Feb; 19(2):7. PubMed ID: 29417238
[TBL] [Abstract][Full Text] [Related]
19. A Case of Uterine Leiomyosarcoma with Long-Term Disease Control by Pazopanib.
Nagamata S; Ebina Y; Yamano Y; Miyamoto T; Nishijima M; Yamada H
Kobe J Med Sci; 2016 Jul; 62(2):E45-8. PubMed ID: 27578036
[TBL] [Abstract][Full Text] [Related]
20. The management of patients with uterine sarcoma: a debated clinical challenge.
Gadducci A; Cosio S; Romanini A; Genazzani AR
Crit Rev Oncol Hematol; 2008 Feb; 65(2):129-42. PubMed ID: 17706430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
